When simple agonism is not enough: emerging modalities of GPCR ligands

Molecular and Cellular Endocrinology
Nicola J SmithGraeme Milligan

Abstract

Recent advances in G protein-coupled receptors have challenged traditional definitions of agonism, antagonism, affinity and efficacy. The discovery of agonist functional selectivity and receptor allosterism has meant researchers have an expanded canvas for designing and discovering novel drugs. Here we describe modes of agonism emerging from the discovery of functional selectivity and allosterism. We discuss the concept of ago-allosterism, where ligands can initiate signaling by themselves and influence the actions of another ligand at the same receptor. We introduce the concept of dualsteric ligands that consist of distinct elements which bind to each of the orthosteric and an allosteric domain on a single receptor to enhance subtype selectivity. Finally, the concept that efficacy should be defined by the activity of an endogenous ligand will be challenged by the discovery that some ligands act as 'super-agonists' in specific pathways or at certain receptor mutations.

References

Jan 1, 1990·Annual Review of Pharmacology and Toxicology·E C HulmeN J Buckley
Jan 15, 1999·Pharmacology & Therapeutics·J Wess
May 17, 2001·Proceedings of the National Academy of Sciences of the United States of America·P GhanouniB K Kobilka
Oct 19, 2001·Proceedings of the National Academy of Sciences of the United States of America·F KnoflachJ A Kemp
May 31, 2002·Pharmacological Reviews·Arthur Christopoulos, Terry Kenakin
Sep 3, 2002·Proceedings of the National Academy of Sciences of the United States of America·Christopher M TanLee E Limbird
Jan 11, 2003·The Journal of Biological Chemistry·Alan WiseNicholas B Pike
Feb 4, 2003·Nature Medicine·Sorin TunaruStefan Offermanns
Dec 1, 1956·British Journal of Pharmacology and Chemotherapy·R P STEPHENSON
Oct 16, 2003·The Journal of Biological Chemistry·Gayathri SwaminathBrian K Kobilka
Dec 6, 2003·Pharmacological Reviews·Richard R NeubigUNKNOWN International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification
Dec 28, 2004·Nature Medicine·Akira HirasawaGozoh Tsujimoto
Jun 25, 2005·Mini Reviews in Medicinal Chemistry·N J M Birdsall, S Lazareno
Jan 13, 2006·British Journal of Pharmacology·Graeme Milligan, Evi Kostenis
Mar 23, 2006·The Journal of Biological Chemistry·Stanislav EngelMarvin C Gershengorn
Apr 6, 2006·Journal of Receptor and Signal Transduction Research·Thue W Schwartz, Birgitte Holst
Jun 7, 2006·The Journal of Biological Chemistry·Jinghong WangLei Ling
Jun 29, 2006·The Journal of Pharmacology and Experimental Therapeutics·Jonathan D UrbanRichard B Mailman
Aug 8, 2006·Trends in Pharmacological Sciences·Christopher J Langmead, Arthur Christopoulos
Sep 13, 2006·The Journal of Biological Chemistry·Jinghong WangLei Ling
Oct 3, 2006·Annual Review of Pharmacology and Toxicology·Lauren T MayArthur Christopoulos
Oct 25, 2006·Proceedings of the National Academy of Sciences of the United States of America·Keshava RajagopalRobert J Lefkowitz
Dec 2, 2006·Nature Reviews. Drug Discovery·John P OveringtonAndrew L Hopkins
May 26, 2007·Molecular Pharmacology·Lauren T MayArthur Christopoulos
Jul 17, 2007·Trends in Pharmacological Sciences·Richard B Mailman
Jul 17, 2007·Trends in Pharmacological Sciences·Katie LeachArthur Christopoulos
Jul 31, 2007·Trends in Pharmacological Sciences·Ségolène GalandrinMichel Bouvier
Sep 6, 2007·The Journal of Clinical Investigation·Takahisa NomaHoward A Rockman
Sep 11, 2007·Bioorganic & Medicinal Chemistry Letters·Min TengJesper Lau
Oct 24, 2007·Nature·Søren G F RasmussenBrian K Kobilka

❮ Previous
Next ❯

Citations

Feb 24, 2011·Biochemistry·Michael R WoodCraig W Lindsley
Oct 19, 2011·Future Medicinal Chemistry·Seetharama D Satyanarayanajois, Ronald A Hill
Feb 9, 2012·International Journal of Hypertension·María Paz Ocaranza, Jorge E Jalil
Aug 19, 2011·Nature Chemical Biology·Jacob Piehler
May 29, 2012·Nature Chemical Biology·Stefanie BlättermannEvi Kostenis
Dec 14, 2011·Expert Opinion on Investigational Drugs·Namrata IyerDipshikha Chakravortty
Jun 26, 2012·Pharmacology & Therapeutics·Christa E MüllerYounis Baqi
Oct 29, 2011·Trends in Pharmacological Sciences·Vsevolod KatritchRaymond C Stevens
Sep 10, 2011·Trends in Pharmacological Sciences·Vsevolod Katritch, Ruben Abagyan
Aug 16, 2015·British Journal of Pharmacology·R SchrageK Mohr
Oct 16, 2012·British Journal of Pharmacology·R SchrageK Mohr
Apr 1, 2012·Molecular Informatics·Agostino Bruno, Gabriele Costantino
Nov 19, 2013·Pharmaceutical Patent Analyst·Craig W Lindsley, Shaun R Stauffer
Nov 2, 2017·Current Protocols in Immunology·Thomas Myles AshhurstNicholas Jonathan Cole King
Jul 21, 2020·ChemMedChem·Zoltán OrgovánGyörgy M Keserű
Nov 3, 2016·British Journal of Pharmacology·Andrew D PowellNicholas M Barnes
Jun 21, 2012·Journal of Receptor and Signal Transduction Research·Sandra Seljeset, Sandra Siehler
Jul 19, 2013·Journal of Medicinal Chemistry·Marvin A Soriano-UrsúaSantiago Vilar
Nov 16, 2021·Journal of Chemical Information and Modeling·Fuhui ZhangXuemei Pu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.